DSGN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -9.82. Updated 2026-07-23.
Design Therapeutics (DSGN) Research Hub
Design Therapeutics (DSGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 14.63 USD (-2.60%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -9.82, market cap 0.73B. This hub links to the full technical, earnings and options research available for DSGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 14.63 USD (-2.60%) |
| 52-week range | 10.78 USD – 16.12 USD |
| Trend regime | Range |
| 14-day RSI | 55.8 (Bullish) |
| Trailing P/E | -9.82 |
| Market cap | 0.73B |
| Dividend yield | 0.00% |
Available research for DSGN
Covered Call on DSGN: how it works, illustrative setup around the real 14.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DSGN: how it works, illustrative setup around the real 14.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DSGN: how it works, illustrative setup around the real 14.63 USD price, max profit/loss, breakeven and when to use it. Educational.
DSGN technical analysis: range, last 14.63 USD, RSI 55.8, 52w range 10.78 USD–16.12 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DSGN in?
Design Therapeutics (DSGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DSGN in an uptrend or downtrend?
As of 2026-09-11, DSGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DSGN's trailing P/E ratio?
DSGN's trailing P/E is -9.82, with a market cap of 0.73B. See the earnings research page for full valuation detail.